Heterogeneous binding and central nervous system distribution of the multitargeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma

Janice K. Laramy, Minjee Kim, Shiv K. Gupta, Karen E. Parrish, Shuangling Zhang, Katrina K. Bakken, Brett L. Carlson, Ann C. Mladek, Daniel J. Ma, Jann N Sarkaria, William F. Elmquist

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This study investigated how differences in drug distribution and free fraction at different tumor and tissue sites influence the efficacy of the multikinase inhibitor ponatinib in a patient-derived xenograft model of glioblastoma (GBM). Efficacy studies in GBM6 flank (heterotopic) and intracranial (orthotopic) models showed that ponatinib is effective in the flank but not in the intracranial model, despite a relatively high brain-to-plasma ratio. In vitro binding studies indicated that flank tumor had a higher free (unbound) drug fraction than normal brain. The total and free drug concentrations, along with the tissue-to-plasma ratio (Kp) and its unbound derivative (Kp,uu), were consistently higher in the flank tumor than the normal brain at 1 and 6 hours after a single dose in GBM6 flank xenografts. In the orthotopic xenografts, the intracranial tumor core displayed higher Kp and Kp,uu values compared with the brain-around-tumor (BAT). The free fractions and the total drug concentrations, hence free drug concentrations, were consistently higher in the core than in the BAT at 1 and 6 hours postdose. The delivery disadvantages in the brain and BAT were further evidenced by the low total drug concentrations in these areas that did not consistently exceed the in vitro cytotoxic concentration (IC50). Taken together, the regional differences in free drug exposure across the intracranial tumor may be responsible for compromising efficacy of ponatinib in orthotopic GBM6.

Original languageEnglish (US)
Pages (from-to)136-147
Number of pages12
JournalJournal of Pharmacology and Experimental Therapeutics
Volume363
Issue number2
DOIs
StatePublished - Nov 1 2017

Fingerprint

Glioblastoma
Heterografts
Phosphotransferases
Central Nervous System
Brain Neoplasms
Pharmaceutical Preparations
Neoplasms
Brain
ponatinib
Inhibitory Concentration 50

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Heterogeneous binding and central nervous system distribution of the multitargeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma. / Laramy, Janice K.; Kim, Minjee; Gupta, Shiv K.; Parrish, Karen E.; Zhang, Shuangling; Bakken, Katrina K.; Carlson, Brett L.; Mladek, Ann C.; Ma, Daniel J.; Sarkaria, Jann N; Elmquist, William F.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 363, No. 2, 01.11.2017, p. 136-147.

Research output: Contribution to journalArticle

Laramy, Janice K. ; Kim, Minjee ; Gupta, Shiv K. ; Parrish, Karen E. ; Zhang, Shuangling ; Bakken, Katrina K. ; Carlson, Brett L. ; Mladek, Ann C. ; Ma, Daniel J. ; Sarkaria, Jann N ; Elmquist, William F. / Heterogeneous binding and central nervous system distribution of the multitargeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma. In: Journal of Pharmacology and Experimental Therapeutics. 2017 ; Vol. 363, No. 2. pp. 136-147.
@article{3997c56e6bdb4aad8d01df7c599257e5,
title = "Heterogeneous binding and central nervous system distribution of the multitargeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma",
abstract = "This study investigated how differences in drug distribution and free fraction at different tumor and tissue sites influence the efficacy of the multikinase inhibitor ponatinib in a patient-derived xenograft model of glioblastoma (GBM). Efficacy studies in GBM6 flank (heterotopic) and intracranial (orthotopic) models showed that ponatinib is effective in the flank but not in the intracranial model, despite a relatively high brain-to-plasma ratio. In vitro binding studies indicated that flank tumor had a higher free (unbound) drug fraction than normal brain. The total and free drug concentrations, along with the tissue-to-plasma ratio (Kp) and its unbound derivative (Kp,uu), were consistently higher in the flank tumor than the normal brain at 1 and 6 hours after a single dose in GBM6 flank xenografts. In the orthotopic xenografts, the intracranial tumor core displayed higher Kp and Kp,uu values compared with the brain-around-tumor (BAT). The free fractions and the total drug concentrations, hence free drug concentrations, were consistently higher in the core than in the BAT at 1 and 6 hours postdose. The delivery disadvantages in the brain and BAT were further evidenced by the low total drug concentrations in these areas that did not consistently exceed the in vitro cytotoxic concentration (IC50). Taken together, the regional differences in free drug exposure across the intracranial tumor may be responsible for compromising efficacy of ponatinib in orthotopic GBM6.",
author = "Laramy, {Janice K.} and Minjee Kim and Gupta, {Shiv K.} and Parrish, {Karen E.} and Shuangling Zhang and Bakken, {Katrina K.} and Carlson, {Brett L.} and Mladek, {Ann C.} and Ma, {Daniel J.} and Sarkaria, {Jann N} and Elmquist, {William F.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1124/jpet.117.243477",
language = "English (US)",
volume = "363",
pages = "136--147",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Heterogeneous binding and central nervous system distribution of the multitargeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma

AU - Laramy, Janice K.

AU - Kim, Minjee

AU - Gupta, Shiv K.

AU - Parrish, Karen E.

AU - Zhang, Shuangling

AU - Bakken, Katrina K.

AU - Carlson, Brett L.

AU - Mladek, Ann C.

AU - Ma, Daniel J.

AU - Sarkaria, Jann N

AU - Elmquist, William F.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - This study investigated how differences in drug distribution and free fraction at different tumor and tissue sites influence the efficacy of the multikinase inhibitor ponatinib in a patient-derived xenograft model of glioblastoma (GBM). Efficacy studies in GBM6 flank (heterotopic) and intracranial (orthotopic) models showed that ponatinib is effective in the flank but not in the intracranial model, despite a relatively high brain-to-plasma ratio. In vitro binding studies indicated that flank tumor had a higher free (unbound) drug fraction than normal brain. The total and free drug concentrations, along with the tissue-to-plasma ratio (Kp) and its unbound derivative (Kp,uu), were consistently higher in the flank tumor than the normal brain at 1 and 6 hours after a single dose in GBM6 flank xenografts. In the orthotopic xenografts, the intracranial tumor core displayed higher Kp and Kp,uu values compared with the brain-around-tumor (BAT). The free fractions and the total drug concentrations, hence free drug concentrations, were consistently higher in the core than in the BAT at 1 and 6 hours postdose. The delivery disadvantages in the brain and BAT were further evidenced by the low total drug concentrations in these areas that did not consistently exceed the in vitro cytotoxic concentration (IC50). Taken together, the regional differences in free drug exposure across the intracranial tumor may be responsible for compromising efficacy of ponatinib in orthotopic GBM6.

AB - This study investigated how differences in drug distribution and free fraction at different tumor and tissue sites influence the efficacy of the multikinase inhibitor ponatinib in a patient-derived xenograft model of glioblastoma (GBM). Efficacy studies in GBM6 flank (heterotopic) and intracranial (orthotopic) models showed that ponatinib is effective in the flank but not in the intracranial model, despite a relatively high brain-to-plasma ratio. In vitro binding studies indicated that flank tumor had a higher free (unbound) drug fraction than normal brain. The total and free drug concentrations, along with the tissue-to-plasma ratio (Kp) and its unbound derivative (Kp,uu), were consistently higher in the flank tumor than the normal brain at 1 and 6 hours after a single dose in GBM6 flank xenografts. In the orthotopic xenografts, the intracranial tumor core displayed higher Kp and Kp,uu values compared with the brain-around-tumor (BAT). The free fractions and the total drug concentrations, hence free drug concentrations, were consistently higher in the core than in the BAT at 1 and 6 hours postdose. The delivery disadvantages in the brain and BAT were further evidenced by the low total drug concentrations in these areas that did not consistently exceed the in vitro cytotoxic concentration (IC50). Taken together, the regional differences in free drug exposure across the intracranial tumor may be responsible for compromising efficacy of ponatinib in orthotopic GBM6.

UR - http://www.scopus.com/inward/record.url?scp=85030768758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030768758&partnerID=8YFLogxK

U2 - 10.1124/jpet.117.243477

DO - 10.1124/jpet.117.243477

M3 - Article

VL - 363

SP - 136

EP - 147

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -